Updating results

Pegargiminase with pemetrexed and cisplatin for untreated advanced malignant pleural mesothelioma [ID1575]

In development [GID-TA10486] Expected publication date: TBC

Technology appraisal guidance In development

Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma [ID1589]

In development [GID-TA10481] Expected publication date: TBC

Technology appraisal guidance In development

Darolutamide for treating non-metastatic hormone-relapsed prostate cancer ID1443

In development [GID-TA10476] Expected publication date: 25 November 2020

Technology appraisal guidance In development

Lenalidomide with R-CHOP for untreated activated diffuse large B-cell lymphoma [ID1611]

In development [GID-TA10480] Expected publication date: TBC

Technology appraisal guidance In development

PneuX for preventing ventilator-associated pneumonia in intensive care

In development [GID-MT528] Expected publication date: 11 March 2020

Medical technologies guidance In development

Encorafenib with binimetinib and cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer

In development [GID-TA10479] Expected publication date: 22 July 2020

Technology appraisal guidance In development

Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527]

In development [GID-TA10483] Expected publication date: TBC

Technology appraisal guidance In development

Abortion care

In development [GID-QS10084] Expected publication date: 18 August 2020

Quality standard In development

Workplace health: long-term sickness absence and management

In development [GID-QS10114] Expected publication date: 13 January 2021

Quality standard In development

Community pharmacies: promoting health and wellbeing

In development [GID-QS10115] Expected publication date: 02 June 2020

Quality standard In development

Elective joint replacement

In development [GID-QS10090] Expected publication date: 13 January 2021

Quality standard In development

Carers: provision of support for adult carers

In development [GID-QS10128] Expected publication date: 04 December 2020

Quality standard In development

Seven day working

In development [GID-QS10108] Expected publication date: TBC

Quality standard In development

Nivolumab with temozolomide and radiotherapy for newly diagnosed glioblastoma with MGMT methylation [ID1582]

In development [GID-TA10495] Expected publication date: 26 August 2020

Technology appraisal guidance In development

Testing strategies for Lynch syndrome in people with endometrial cancer

In development [GID-DG10033] Expected publication date: 29 July 2020

Diagnostics guidance In development

Gilteritinib for treating relapsed or refractory acute myeloid leukaemia [ID1484]

In development [GID-TA10460] Expected publication date: 26 February 2020

Technology appraisal guidance In development

Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy ID1536

In development [GID-TA10466] Expected publication date: 15 January 2020

Technology appraisal guidance In development

Lung cancer (non-small-cell, EGFR and T790M positive, metastatic) - osimertinib (CDF Review of TA416) [ID1577]

In development [GID-TA10475] Expected publication date: 22 April 2020

Technology appraisal guidance In development

Lisocabtagene maraleucel for treating large B-cell lymphoma after at least 2 therapies ID1444

In development [GID-TA10477] Expected publication date: 09 December 2020

Technology appraisal guidance In development

Heavy menstrual bleeding (QS update)

In development [GID-QS10134] Expected publication date: 23 June 2020

Quality standard In development

Idasanutlin with cytarabine for treating relapsed or refractory acute myeloid leukaemia [ID1597]

In development [GID-TA10494] Expected publication date: TBC

Technology appraisal guidance In development

Enzalutamide with androgen deprivation therapy for treating metastatic hormone-sensitive prostate cancer ID1605

In development [GID-TA10488] Expected publication date: 05 August 2020

Technology appraisal guidance In development

Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer [ID1516]

In development [GID-TA10468] Expected publication date: 10 June 2020

Technology appraisal guidance In development

Durvalumab in combination for untreated extensive stage small-cell lung cancer [ID1618]

In development [GID-TA10493] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer after chemotherapy [ID1621]

In development [GID-TA10492] Expected publication date: TBC

Technology appraisal guidance In development

Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma [ID1620]

In development [GID-TA10491] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer before chemotherapy [ID1619]

In development [GID-TA10490] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab with ipilimumab for adjuvant treatment of completely resected stage III or IV melanoma ID1610

In development [GID-TA10499] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma [ID1609]

In development [GID-TA10498] Expected publication date: 23 June 2021

Technology appraisal guidance In development

Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly ID1596

In development [GID-TA10497] Expected publication date: 02 December 2020

Technology appraisal guidance In development

Encorafenib with binimetinib and cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer ID1598

In development [GID-TA10496] Expected publication date: 21 October 2020

Technology appraisal guidance In development

Venetoclax with a hypomethylating agent or low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable ID1564

In development [GID-TA10478] Expected publication date: 10 February 2021

Technology appraisal guidance In development

Fetal alcohol spectrum disorder

In development [GID-QS10139] Expected publication date: 31 July 2020

Quality standard In development

Trifluridine–tipiracil for treating metastatic gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID1507]

In development [GID-TA10456] Expected publication date: TBC

Technology appraisal guidance In development

Fenfluramine for treating Dravet syndrome [ID1109]

In development [GID-TA10373] Expected publication date: TBC

Technology appraisal guidance In development

Fetoscopic prenatal repair for open neural tube defects in the fetus

In development [GID-IPG10120] Expected publication date: 29 January 2020

Interventional procedures guidance In development

Canakinumab for preventing cardiovascular events after myocardial infarction in people with raised high-sensitivity C-reactive protein (ID1362)

In development [GID-TA10337] Expected publication date: 19 February 2020

Technology appraisal guidance In development

gammaCore for cluster headache

In development [GID-MT523] Expected publication date: 03 December 2019

Medical technologies guidance In development

Budesonide for treating active eosinophilic oesophagitis [ID1202]

In development [GID-TA10372] Expected publication date: 08 July 2020

Technology appraisal guidance In development

Fever in under 5s: assessment and initial management

In development [GID-NG10138] Expected publication date: 07 November 2019

NICE guideline In development

Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]

In development [GID-TA10446] Expected publication date: TBC

Technology appraisal guidance In development

ATIR101 with haploidentical haematopoietic stem cell transplantation for haematological cancers [ID1093]

In development [GID-TA10445] Expected publication date: TBC

Technology appraisal guidance In development

Rivaroxaban for preventing major cardiovascular events in people with coronary or peripheral artery disease [ID1397]

In development [GID-TA10347] Expected publication date: 17 October 2019

Technology appraisal guidance In development

Isatuximab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma [ID1477]

In development [GID-TA10448] Expected publication date: 05 August 2020

Technology appraisal guidance In development

Ublituximab with ibrutinib for previously treated chronic lymphocytic leukaemia [ID1476]

In development [GID-TA10447] Expected publication date: TBC

Technology appraisal guidance In development

Avatrombopag and lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing an elective procedure [ID1520]

In development [GID-TA10444] Expected publication date: 26 February 2020

Technology appraisal guidance In development

Human and animal bites: antimicrobial prescribing

In development [GID-NG10137] Expected publication date: 30 June 2020

Antimicrobial prescribing guideline In development

Leg ulcer infection: antimicrobial prescribing

In development [GID-NG10133] Expected publication date: 13 December 2019

Antimicrobial prescribing guideline In development

Insect bites and stings: antimicrobial prescribing

In development [GID-NG10136] Expected publication date: TBC

Antimicrobial prescribing guideline In development